Chloé BESSIERE

Post-doc in #bioinformatics at the #CRCT in #Toulouse

[CRCT-Oncopole @crctoncopole]

#RETRAITECRCT
Les fondateurs de l’association des postdocs du CRCT @Crct_Postdoc, Benoît Aliaga (@Benoit3166), @Steffen_E_Fuchs et @ChloeBessiere sont venus présenter les missions du club et leur congrès du jeudi 5 octobre à l'@IUCTOncopole.
En savoir +➡️https://t.co/WCL9hbWf6b

[Steffen Fuchs @Steffen_E_Fuchs]

If you're still looking for a chance to present your recent cancer research results, why not coming to #Toulouse? We extended the submission deadline to August 3.
Further, @EnfantsCancers will award 2 presentations for the best pediatric oncology presentation!
See you at #YS2C

[CRCT postdoc @Crct_Postdoc]

Last day at #ISMBECCB2023. 2 postdocs, 2 engineers and 1 PhD student from @crctoncopole presented their works.

[CRCT postdoc @Crct_Postdoc]

@ChloeBessiere postdoc in @RnbloodC team will present her poster (C-348) at #ISMBECCB2023 Lyon 18:00. #iRNACOSI track.

[anna-sophie fiston-lavier @afiston]

So nice to meet former master students from the master program of Montpellier….5 generations at the international bioinformatic conference #ismbeccb2023 @umontpellier @FacsciencesUM #bioinformatics @Seajulll @TintestBioinfo @Benoit3166 @ChloeBessiere @Corentinmarco34

[Benoît Aliaga @Benoit3166]

With @ChloeBessiere and @Steffen_E_Fuchs, we funded the @Crct_Postdoc. Now with other colleagues from @CanceropoleGSO, we are organizing the 1st Young Scientist Cancer Congress, which takes place at the IUCT, Toulouse.

Save the date: October 5, 2023 #Cancer #Research #Clinic

[Steffen Fuchs @Steffen_E_Fuchs]

Thrilled to announce that we organize THE FIRST YOUNG SCIENTIST CANCER CONFERENCE in SOUTH-WESTER FRANCE #YS2C_GSO at the Cancer Research Center of Toulouse. Keynote lectures feature Manel Esteller (Barcelona), Olivier Delattre (Paris), and Francesco Ioro (Cambridge/Milan).

[Gene Regulation @generegulation]

Probing instructions for expression regulation in gene nucleotide compositions https://t.co/gs5g4l9Zwu ∼87% TADs are characterized by at least one specific nucleotide signature; distinct classes of TADs in agreement with the isochore model --> different mRNA abundance